# Extension of Study ZPV-200

> **NCT01631903** · PHASE2 · COMPLETED · sponsor: **Repros Therapeutics Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** telepristone acetate 12 mg
- **DRUG:** telepristone acetate 3 mg
- **DRUG:** telepristone acetate 6 mg
- **DRUG:** telepristone acetate 12 mg
- **DRUG:** telepristone acetate 24 mg

## Key facts

- **NCT ID:** NCT01631903
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2014-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01631903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01631903, "Extension of Study ZPV-200". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01631903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*